PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)
Launched by MERCK SHARP & DOHME LLC · Jun 13, 2002
Trial Information
Current as of June 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age at entry 18-65
- • Positive for Hepatitis C
- • Nonresponder to previous treatment (minimum of 3 months) with an alpha Interferon plus ribavirin
- • Liver biopsy demonstrating moderate to severe fibrosis or cirrhosis
- Exclusion Criteria:
- • Any cause for the liver disease other than chronic hepatitis C
- • History or presence of complications of cirrhosis
- • Alcohol or illicit drug use or methadone treatment within the past 2 years
- • Treatment for chronic hepatitis C within the previous 6 months
- • Diseases or conditions that could interfere with the subject's participation in and completion of the study
About Merck Sharp & Dohme Llc
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., is a leading global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and vaccines that address unmet medical needs. With a strong focus on research and development, Merck Sharp & Dohme leverages advanced science and technology to enhance patient outcomes across various therapeutic areas, including oncology, infectious diseases, and cardiovascular health. Committed to ethical practices and regulatory compliance, the company actively engages in clinical trials to advance medical knowledge and improve health care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials